Watch Ticker

Immunovant, Inc. Common Stock

Go to Immunovant, Inc. Common Stock Website

$16.05

0.34 (2.16%)

Live

Previous Close

$16.09

Day Range

$15.49 - $16.11

Previous Day Range

$15.37 - $16.03

Market Cap

$2.7 billion USD

Day Vol.

716033

Previous Day Vol.

1.5 million

Currency

USD

Primary Exchange

Nasdaq

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to addr...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Zacks, Benzinga Contributor - IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

Immunovant's (IMVT) investigational candidate, batoclimab, showed positive data in a mid-stage study for Graves' Disease, leading to a rise in the company's stock. The data demonstrated significant reductions in Immunoglobin G levels and high response rates in the patient population.

Related tickers: IMVT, ILMN, KRYS, FULC.

Read Full Article

N/A - Immunovant Provides Update on Graves’ Disease Development Program

Immunovant's batoclimab achieved a 76% response rate in Graves' Disease patients uncontrolled on antithyroid drugs (ATDs) at week 12. The company also reported a strong correlation between IgG lowering and clinical outcomes, indicating a potential best-in-class and first-in-class opportunity for IMVT-1402 in Graves' Disease.

Related tickers: IMVT.

Read Full Article

Trending Tickers

Please sign in to view